Two roads for oncolytic immunotherapy development

por Kaufman, Howard L., Bommareddy, Praveen K.
Publicado 2019

An update on TroVax(®) for the treatment of progressive castration-resistant prostate cancer

por Abern, Michael, Kaufman, Howard L, Latchamsetty, Kalyan
Publicado 2011

Oncolytic viruses: a new class of immunotherapy drugs

por Kaufman, Howard L., Kohlhapp, Frederick J., Zloza, Andrew
Publicado 2015

Erratum: Oncolytic viruses: a new class of immunotherapy drugs

por Kaufman, Howard L., Kohlhapp, Frederick J., Zloza, Andrew
Publicado 2016

Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class

por Kaufman, Howard L., Shalhout, Sophia Z., Iodice, Gail
Publicado 2022

Recursive SVM biomarker selection for early detection of breast cancer in peripheral blood

por Zhang, Fan, Kaufman, Howard L, Deng, Youping, Drabier, Renee
Publicado 2013

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade

por Bommareddy, Praveen K., Rabkin, Samuel D., Kaufman, Howard L.
Publicado 2019

Immunotherapy for Merkel cell carcinoma: a turning point in patient care

por Chan, Isaac S., Bhatia, Shailender, Kaufman, Howard L., Lipson, Evan J.
Publicado 2018

Clinical landscape of oncolytic virus research in 2020

por Macedo, Nicholas, Miller, David M, Haq, Rizwan, Kaufman, Howard L
Publicado 2020

Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma

por Kaufman, Howard L, Ruby, Carl E, Hughes, Tasha, Slingluff, Craig L
Publicado 2014

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy

por Rehman, Hasan, Silk, Ann W., Kane, Michael P., Kaufman, Howard L.
Publicado 2016

Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma

por Bommareddy, Praveen K., Zloza, Andrew, Rabkin, Samuel D., Kaufman, Howard L.
Publicado 2019

Immunotherapy for Non-melanoma Skin Cancer

por Shalhout, Sophia Z., Emerick, Kevin S., Kaufman, Howard L., Miller, David M.
Publicado 2021

Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma

por Hughes, Tasha, Coffin, Robert S, Lilley, Caroline E, Ponce, Rafael, Kaufman, Howard L
Publicado 2014

Role of dose selection in successful interleukin-2 immunotherapy: solving the Goldilock’s Complex

por Zloza, Andrew, Broucek, Joseph R, Huelsmann, Erica J, Hughes, Tasha, Kaufman, Howard L
Publicado 2013

Living with Merkel Cell Carcinoma (MCC): Development of a Conceptual Model of MCC Based on Patient Experiences

por Kaufman, Howard L., Dias Barbosa, Carla, Guillemin, Isabelle, Lambert, Jérémy, Mahnke, Lisa, Bharmal, Murtuza
Publicado 2018

Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma

por Nghiem, Paul, Kaufman, Howard L, Bharmal, Murtuza, Mahnke, Lisa, Phatak, Hemant, Becker, Jürgen C
Publicado 2017

Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma

por Bommareddy, Praveen K., Lowe, Devin B., Kaufman, Howard L., Rabkin, Samuel D., Saha, Dipongkor
Publicado 2019

Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an...

por Shafren, Darren, Quah, Min, Wong, Yvonne, Andtbacka, Robert HI, Kaufman, Howard L, Au, Gough G
Publicado 2014

Cancer immunotherapy trials: leading a paradigm shift in drug development

por Emens, Leisha A., Butterfield, Lisa H., Hodi, F. Stephen, Marincola, Francesco M., Kaufman, Howard L.
Publicado 2016